Standards minimise risk of misconnections; eltrombopag interference with test results; amniotic fluid tests
Therapeutic Goods Administration - Australia
Europe - EMA - European Medicines Agency
Revolade (Active substance: Eltrombopag) - PSUSA - Modification - Commission Decision (2018)4487 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/1205/201709
Europe -DG Health and Food Safety
Registration is free.
myHealthbox can improve the online visibility of your products by as much as 20%.
Contact us to find out more.
myHealthbox™ is a leading provider of health information services to consumers and healthcare professionals.